European shares end marginally lower on tech drag; Fed in focus
For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
France's Rexel jumps after rejecting $9.4 bln QXO bid
UK insurer Phoenix falls on halting sale of unit SunLife
STOXX 600 down 0.2%
Updated at 1600 GMT
By Shubham Batra and Shashwat Chauhan
Sept 16 (Reuters) -Europe's STOXX 600 closed slightly lower on Monday as losses in heavyweight technology shares weighed on the index, while the focus remained on the U.S. Federal Reserve, which is widely expected to kick off its policy easing cycle this week.
The pan-European STOXX 600 index .STOXX ended 0.2% lower, snapping a three-day winning streak.
Europe's tech index .SX8P dipped 1.2%, the biggest percentage decliner amongst major STOXX sectors, following its near 5% jump last week.
Retail .SXRP led advances with an 0.9% rise, boosted by a 3.1% increase in H&M HMb.ST.
All eyes will be on the U.S. central bank's interest rate decision on Wednesday, with money markets pencilling in a 61% chance of a 50-basis-point rate cut, and a total easing of 120 bps in 2024.
"With the Fed set to hop aboard the (rate-cut) bandwagon, a global easing cycle should be a tailwind for equities after the European Central Bank opted to cut rates for the second time in three months," wrote analysts at Glenmede led by Jason Pride, chief of investment strategy & research.
"Momentum behind global easing cycles has historically been a bullish signal for equities in the short-to-medium term."
Central bank rate decisions in Norway and the UK will also be on investors' radar this week.
The ECB's chief economist Philip Lane said the bank should keep cutting interest rates gradually, but its policymakers expressed differing views on how to signal their intent given economic uncertainty.
Among individual movers, France's Rexel RXL.PA jumped 9.1% after the Paris-listed group rebuffed an around $9.4 billion acquisition offer from billionaire Brad Jacobs-led QXO QXO.O.
French drugmaker Ipsen IPN.PA rose 3.7% after RBC raised its rating to "outperform" from "sector perform", seeing mid-term support from its liver disease drug Iqirvo (PBC) after its U.S. FDA approval in June.
On the flip side, shares of Nestle NESN.S weighed on the benchmark index with a 1% fall after Morgan Stanley cut the stock's rating to "underweight" and reduced its target price.
France's Worldline WLN.PA slumped 15.2%, extending losses from Friday when the payments group said its long-time CEO Gilles Grapinet would leave the company as it issued its third profit warning.
Phoenix Group PHNX.L shed 5.3% after the British insurer halted the sale process of its SunLife business due to market uncertainty.
Reporting by Shubham Batra and Shashwat Chauhan in Bengaluru; Editing by Sherry Jacob-Phillips, Abinaya Vijayaraghavan and Jonathan Oatis
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
